Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040937 · ClinicalTrials.gov registry record · Phase 2

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
147
Enrollment target
20
Study locations

NCT00040937: Completed Phase 2 study of Multiple Myeloma, sponsored by SWOG Cancer Research Network.

NCT00040937 is a Phase 2 study of Multiple Myeloma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 147 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040937, a Phase 2 study of Multiple Myeloma, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
147 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving thalidomide before and after peripheral stem cell transplant may be effective in treating newly diagnosed multiple myeloma. PURPOSE: This phase II trial is studying how well giving thalidomide with chemotherapy and peripheral stem cell transplant work in treating patients with newly diagnosed multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG cyclophosphamide
  • DRUG dexamethasone
  • DRUG melphalan
  • BIOLOGICAL filgrastim
  • BIOLOGICAL sargramostim

Study Locations (20)

Georgia

  • Piedmont Hospital - Atlanta
  • CCOP - Atlanta Regional - Atlanta
  • Northside Hospital Cancer Center - Atlanta
  • Saint Joseph's Hospital of Atlanta - Atlanta
  • WellStar Cobb Hospital - Austell
  • Charles B. Eberhart Cancer Center at DeKalb Medical Center - Decatur
  • Gwinnett Medical Center - Lawrenceville
  • Kennestone Cancer Center at Wellstar Kennestone Hospital - Marietta
  • Southern Regional Medical Center - Riverdale

Hawaii

  • Cancer Research Center of Hawaii - Honolula
  • OnCare Hawaii, Incorporated - Lusitana - Honolulu
  • Queen's Cancer Institute at Queen's Medical Center - Honolulu
  • Straub Clinic and Hospital, Incorporated - Honolulu
  • OnCare Hawaii, Incorporated - Kuakini - Honolulu
  • St. Francis Medical Center - Honolulu
  • Kapiolani Medical Center for Women and Children - Honolulu

California

  • University of California Davis Cancer Center - Davis
  • Sutter Roseville Medical Center - Roseville
  • Sutter Cancer Center - Sacramento

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2002-06
Est. Completion 2015-10
Phase Phase 2
SWOG Cancer Research Network

270 total trials

What the finished NCT00040937 record still lists

NCT00040937 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00040937 names 20 study sites across 4 states, led by Georgia, Hawaii, California.

Frequently Asked Questions

What is clinical trial NCT00040937 about?

NCT00040937 is a clinical study titled "S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma". RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give ...

What is the current status of trial NCT00040937?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2002-06. Estimated completion is 2015-10.

What conditions does trial NCT00040937 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00040937?

The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00040937?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00040937 being conducted?

This trial has 20 study locations across Arkansas, California, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00040937's enrollment target sits among peer trials

147 136th of 438 higher than 302 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06184516 · 147 participants · Phase 2

    Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00040937, the US trial registry maintained by the National Library of Medicine. NCT00040937 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.